Estudo randomizado | Efeito do denosumabe adicionado a dois regimes diferentes com nab-paclitaxel como terapia neoadjuvante em pacientes com câncer de mama primário.

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)

Comentário no Twitter

In a randomized clinical trial in 780 pts with #breastcancer, addition of denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy with two different nab-paclitaxel schedules did not increase the pCR rate (41% vs 43% without denosumab): https://t.co/gPu6hrSp7z #bcsm

— NatureRevClinOncol (@NatRevClinOncol) May 24, 2022